Dainippon Sumitomo Pharma Co., Ltd. (DSP) plans to launch in Japan donepezil hydrochloride tablets/OD tablets 3mg/5mg “DSP” on December 2, 2011 for the treatment of Alzheimer's disease (AD).

In domestic pharmaceuticals, DSP designates the Central Nervous System (CNS) field as one of its focus marketing areas, and offers various treatments such as atypical antipsychotics “Lonasen” and “Lullan”, Parkinson's disease drug “Trerief”, norepinephrine-activating neural function ameliorant “DOPS”, anti-epileptic drug “Excegran”, and serotonin-agonist antianxiety drug “Sediel”. Approximately 230 CNS MRs in the CNS Sales & Marketing Division newly established in April 2011 are developing activities to provide information on these products.

DSP decided to handle a CNS generic drug as part of a plan to strengthen its product lineup in the CNS area. On June 24, 2011, DSP created “Established Products & Chain Pharmacies Groups” dedicated to generic drugs in the CNS area under CNS Sales and Marketing, each under the CNS Higashi-Nippon Region, CNS Capital Region, CNS Kinki-Tokai Region and CNS Nishi-Nippon Region with the aim to promote sales of generic drugs in the CNS area.

In regard to the detailing of Donepezil hydrochloride tablets/OD tablets 3mg/5mg “DSP”, full-time CNS MRs will detail in their representative areas, while in the representative areas for general MRs, detailing will be in conjuction with the Established Products & Chain Pharmacies Groups and general MRs.

In the future, DSP will positively invest in products to contribute to the treatment of CNS disorders regardless of whether they are new or generic drugs.

Dainippon Sumitomo Pharma Co., Ltd., a Japanese-based company that broadly contributes to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives for people worldwide.